Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
3,148,458
-
Total 13F shares
-
1,080,160
-
Share change
-
+1,004,718
-
Total reported value
-
$38,124,773
-
Price per share
-
$2.83
-
Number of holders
-
16
-
Value change
-
+$37,905,403
-
Number of buys
-
5
-
Number of sells
-
6
Institutional Holders of GT Biopharma, Inc. - Common Stock (GTBP) as of Q2 2024
As of 30 Jun 2024,
GT Biopharma, Inc. - Common Stock (GTBP) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,080,160 shares.
The largest 10 holders included
DekaBank Deutsche Girozentrale, BANK OF MONTREAL /CAN/, SUSQUEHANNA INTERNATIONAL GROUP, LLP, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, WELLS FARGO & COMPANY/MN, BlackRock Inc., UBS Group AG, Tower Research Capital LLC (TRC), and MORGAN STANLEY.
This page lists
16
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.